# US 2023/0381291 A1 · Tumor-associated peptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0381291 A1
- Document ID: US20230381291A1
- Status: Published application
- Kind: A1
- Application number: 18/004,831
- Filed: 2021-07-08
- Published: 2023-11-30
- Earliest claimed: 2020-07-10
- Assignees: Humanitas Mirasole S.P.A.; Humanitas University; Istituto Europeo di Oncologia S.r.l.
- Applicants: Humanitas Mirasole S.P.A.; Humanitas University; Istituto Europeo Di Oncologia S.R.L.
- Inventors: Maria RESCIGNO; Alessia MELACARNE; Giuseppe PENNA
- Web page: https://patentgrep.com/patent/US20230381291A1

## CPC

- A61K 40/4562: {Salmonella; Shigella}
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4271: {Melanoma antigens}
- A61K 40/4272: {Melan-A/MART}
- A61P 37/04: Immunostimulants
- A61K 2039/876: {Skin, melanoma}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides antigen presenting cells (APC) carrying human tumor-associated peptides on the cell surface as well as immunogenic compositions including the tumor-associated peptides and/or the antigen presenting cells according to the invention. The immunogenic composition of the invention is useful as a vaccine in the prevention and/or treatment of a tumor disease, particularly melanoma and melanoma residual disease.

## Claims

### Claim 1

An isolated antigen-presenting cell (APC), which carries on the cell surface one or more tumor-associated peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs. 1-4 and 6-13, fragments of said amino acid sequences SEQ ID NOs. 1-4 and 6-13 of at least 3 amino acids in length, and any combination thereof.

### Claim 2 (depends on 1)

The isolated antigen-presenting cell (APC) according to claim 1, which carries on the cell surface a tumor-associated peptide comprising SEQ ID NO. 1, a tumor-associated peptide comprising SEQ ID NO. 2, a tumor-associated peptide comprising SEQ ID NO. 3 and a tumor-associated peptide comprising SEQ ID NO. 4.

### Claim 3 (depends on 1)

The isolated antigen-presenting cell (APC) according to claim 1, which carries on the cell surface a tumor-associated peptide comprising SEQ ID NO. 1, a tumor-associated peptide comprising SEQ ID NO. 2, a tumor-associated peptide comprising SEQ ID NO. 3, a tumor-associated peptide comprising SEQ ID NO. 4, a tumor-associated peptide comprising SEQ ID NO. 7, a tumor-associated peptide comprising SEQ ID NO. 8, a tumor-associated peptide comprising SEQ ID NO. 11, a tumor-associated peptide comprising SEQ ID NO. 12 and a tumor-associated peptide comprising SEQ ID NO. 13.

### Claim 4 (depends on 1)

The isolated antigen-presenting cell (APC) according to claim 1, which carries on the cell surface a tumor-associated peptide comprising SEQ ID NO. 1, a tumor-associated peptide comprising SEQ ID NO. 2, a tumor-associated peptide comprising SEQ ID NO. 3, a tumor-associated peptide comprising SEQ ID NO. 4, a tumor-associated peptide comprising SEQ ID NO. 6, a tumor-associated peptide comprising SEQ ID NO. 7, a tumor-associated peptide comprising SEQ ID NO. 8, a tumor-associated peptide comprising SEQ ID NO. 9, a tumor-associated peptide comprising SEQ ID NO. 10, a tumor-associated peptide comprising SEQ ID NO. 11, a tumor-associated peptide comprising SEQ ID NO. 12 and a tumor-associated peptide comprising SEQ ID NO. 13.

### Claim 5 (depends on 1)

The isolated antigen-presenting cell (APC) according to claim 1, which is a dendritic cell.

### Claim 6 (depends on 5)

An immunogenic composition comprising:
(i) one or more tumor-associated peptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs. 1-4 and 6-13, fragments of said amino acid sequences SEQ ID NOs. 1-4 and 6-13 of at least 3 amino acids in length, and any combination thereof;
(ii) one or more isolated nucleic acid sequences encoding the tumor-associated peptide(s) of (i);
(iii) one or more expression vectors comprising the nucleic acid sequence(s) of (ii); and/or
(iv) one or more antigen-presenting cells (APC) according to claim 5, and a pharmaceutically acceptable vehicle.

### Claim 7 (depends on 6)

The immunogenic composition according to claim 6, which comprises a tumor-associated peptide comprising SEQ ID NO. 1, a tumor-associated peptide comprising SEQ ID NO. 2, a tumor-associated peptide comprising SEQ ID NO. 3 and a tumor-associated peptide comprising SEQ ID NO. 4.

### Claim 8 (depends on 6)

The immunogenic composition according to claim 6, which comprises a tumor-associated peptide comprising SEQ ID NO. 1, a tumor-associated peptide comprising SEQ ID NO. 2, a tumor-associated peptide comprising SEQ ID NO. 3, a tumor-associated peptide comprising SEQ ID NO. 4, a tumor-associated peptide comprising SEQ ID NO. 7, a tumor-associated peptide comprising SEQ ID NO. 8, a tumor-associated peptide comprising SEQ ID NO. 11, a tumor-associated peptide comprising SEQ ID NO. 12 and a tumor-associated peptide comprising SEQ ID NO. 13.

### Claim 9 (depends on 6)

The immunogenic composition according to claim 6, which comprises a tumor-associated peptide comprising SEQ ID NO. 1, a tumor-associated peptide comprising SEQ ID NO. 2, a tumor-associated peptide comprising SEQ ID NO. 3, a tumor-associated peptide comprising SEQ ID NO. 4, a tumor-associated peptide comprising SEQ ID NO. 6, a tumor-associated peptide comprising SEQ ID NO. 7, a tumor-associated peptide comprising SEQ ID NO. 8, a tumor-associated peptide comprising SEQ ID NO. 9, a tumor-associated peptide comprising SEQ ID NO. 10, a tumor-associated peptide comprising SEQ ID NO. 11, a tumor-associated peptide comprising SEQ ID NO. 12 and a tumor-associated peptide comprising SEQ ID NO. 13.

### Claim 10 (depends on 6)

The immunogenic composition according to claim 6, optionally further containing an adjuvant, for use as a vaccine.

### Claim 11 (depends on 10)

The immunogenic composition for use as a vaccine according to claim 10, in a combination therapy with an immune checkpoint inhibitor, a chemotherapeutic agent, a biologicals, target therapy and/or an oncolytic virus.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 6)

A method of preventing and/or treating melanoma in a subject in need thereof, said method comprising administering to the subject an immunogenic composition as defined in claim 6, wherein said administration induces an immune response against melanoma cells.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the melanoma is a tumor residual disease.

### Claim 16 (depends on 6)

A method of inducing an immune response against melanoma cells in a subject in need thereof, said method comprising administering to the subject an immunogenic composition as defined in claim 6.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the immune response is a cell-mediated immune response.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the cell-mediated immune response involves the activation of cytotoxic T lymphocytes (CTLs).
